Literature DB >> 8195403

Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test.

T Jauhiainen1, T Tuomi, M Leinonen, J D Kark, P Saikku.   

Abstract

In the microimmunofluorescence test for measuring immunoglobulin A (IgA) antibodies against Chlamydia pneumoniae, removal of interfering IgG antibodies made IgA antibody reactivity patterns in 952 serum samples easier to interpret, prozone effects disappeared, and titers increased, especially in the sera with high IgG titers. IgA rheumatoid factors did not interfere in the assay.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8195403      PMCID： PMC263136          DOI： 10.1128/jcm.32.3.839-840.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

2.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

3.  The antigen-limited nature of microtiter ELISAs requires partial depletion of IgG to permit reliable determination of rabbit serum IgA antibody activity.

Authors:  J E Butler; Y Heo; P Adams; H B Richerson
Journal:  Mol Immunol       Date:  1990-04       Impact factor: 4.407

4.  Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor.

Authors:  R P Verkooyen; M A Hazenberg; G H Van Haaren; J M Van Den Bosch; R J Snijder; H P Van Helden; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

5.  Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test.

Authors:  S P Wang; J T Grayston
Journal:  Am J Ophthalmol       Date:  1970-09       Impact factor: 5.258

6.  Inhibition of antichlamydial IgM antibody by IgG antibody in immunofluorescence tests.

Authors:  S V Juchau; W D Linscott; J Schachter; E Jawetz
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

7.  Serum IgG and IgA antibodies to Chlamydia in ectopic pregnancies.

Authors:  W Chaim; B Sarov; I Sarov; B Piura; A Cohen; V Insler
Journal:  Contraception       Date:  1989-07       Impact factor: 3.375

8.  Which antigen to use in the detection of rheumatoid factors? Comparison of patients with rheumatoid arthritis and subjects with 'false positive' rheumatoid factor reactions.

Authors:  T Tuomi
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

9.  Measurement of immunoglobulin M (IgM), IgG, and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease.

Authors:  K Granfors
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

10.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.

Authors:  P Saikku; M Leinonen; L Tenkanen; E Linnanmäki; M R Ekman; V Manninen; M Mänttäri; M H Frick; J K Huttunen
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391
  10 in total
  9 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma.

Authors:  D L Hahn; T Anttila; P Saikku
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

3.  Prevalence of antibodies to Chlamydia pneumoniae in an Israeli population without clinical evidence of respiratory infection.

Authors:  M Ben-Yaakov; G Eshel; L Zaksonski; Z Lazarovich; I Boldur
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

4.  ELISPOT assay for Chlamydia-specific, antibody-producing cells correlated with conventional complement fixation and microimmunofluorescence.

Authors:  H Daugharty; T O Messmer; B S Fields
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

7.  Performance of three microimmunofluorescence assays for detection of Chlamydia pneumoniae immunoglobulin M, G, and A antibodies.

Authors:  Mette Bennedsen; Lene Berthelsen; Inga Lind
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

8.  Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one enzyme immunoassay kit.

Authors:  Mika Paldanius; Aini Bloigu; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

9.  Chlamydia pneumoniae and exacerbations of asthma in adults.

Authors:  N Miyashita; Y Kubota; M Nakajima; Y Niki; H Kawane; T Matsushima
Journal:  Ann Allergy Asthma Immunol       Date:  1998-05       Impact factor: 6.347
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.